Coronado Biosciences Rating Increased to Outperform at Zacks (CNDO)
Coronado Biosciences (NASDAQ:CNDO) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued to investors on Tuesday. The firm currently has a $2.80 price target on the stock. Zacks‘s target price indicates a potential upside of 66.67% from the company’s current price.
Coronado Biosciences (NASDAQ:CNDO) traded down 2.89% during mid-day trading on Tuesday, hitting $1.68. The stock had a trading volume of 159,931 shares. Coronado Biosciences has a 52-week low of $1.25 and a 52-week high of $10.20. The stock’s 50-day moving average is $1.76 and its 200-day moving average is $2.15. The company’s market cap is $74.4 million.
Coronado Biosciences (NASDAQ:CNDO) last announced its earnings results on Monday, May 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.01. On average, analysts predict that Coronado Biosciences will post $-0.75 earnings per share for the current fiscal year.
Coronado Biosciences, Inc is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.